Introduction
Angiotensin-I-converting enzyme (ACE) is a key enzyme in the regulation of peripheral blood pressure. ACE, a dipeptide-liberating carboxypeptidase (peptidyldipeptide hydrolase, EC 3.4.15.1), classically associated with the renin±angiotensin system, converts angiotensin I into angiotensin II, a highly potent vasoconstrictor molecule (Skeegs et al. 1956 ). Several endogenous peptides such as enkephalins, bradykinin and substance P are inhibitors and competitive substrates for ACE (Maruyama et al. 1987a; Steve et al. 1988) . In the kinin kallikrein system, for example, ACE activates bradykinin, a vasodilatory molecule (Erdos, 1975) . This enzyme, therefore, plays a key physiological role in the regulation of local levels of several endogenous bioactive peptides. Exogenous ACE inhibitors having an antihypertensive effect in vivo were first discovered in snake venom (Ondetti et al. 1977) . Several food protein sources including fish, gelatin and maize protein contain ACE-inhibitory peptides (for reviews see Ariyoshi, 1993; Meisel, 1993) . Milk proteins are also precursors for a range of peptides which inhibit ACE (Meisel, 1993; Takano, 1998; FitzGerald & Meisel, 1999) . Casein-derived inhibitors of ACE are known as casokinins (Meisel, 1993) , whereas whey-derived inhibitors are known as lactokinins (FitzGerald & Meisel, 1999) .
General structural features of milk protein-derived ACE inhibitory peptides
Casokinin sequences have been found in a s1 -, b-, and kcasein, and lactokinins in a-lactalbumin, b-lactoglobulin and bovine serum albumin (Tables 1 and 2 ). Two strategies have generally been used in the identification and characterisation of such peptides, i.e. isolation of inhibitory peptides from in vitro enzymatic digests of milk proteins and chemical synthesis of peptides or peptide analogues having similar structures to those known to inhibit ACE. Structure±activity correlations between different peptide inhibitors of ACE indicate that binding to ACE is strongly influenced by the C-terminal tripeptide sequence of the substrate. Although the precise substrate specificity is not fully understood, ACE appears to prefer substrates or competitive inhibitors containing hydrophobic (aromatic or branched side-chains) amino acid residues at each of the three C-terminal positions. ACE inhibition studies with dipeptides of varying structure, show that C-terminal tryptophan, tyrosine, phenylalanine or proline residues were most effective in enhancing substrate binding (Cheung et al. 1980) . All casokinins, i.e. casein-derived ACE inhibitory peptides have proline, lysine or arginine as the C-terminal residue (Table 1) . However, the presence of positively charged C-terminal lysine or arginine residues in casokinins, bradykinin and some synthetic inhibitors (Cheung et al. 1980) does not fit with the ACE active site model proposed by Ondetti & Cushman (1982) . Nevertheless, structure±activity data suggest that the positive charge on the guanidino or 1-amino group of Cterminal arginine and lysine side-chains, respectively, contribute substantially to inhibitory potency. For example, replacement of arginine at the C-terminus of bradykinin results in an essentially inactive analogue (Meisel, 1993) . It is postulated that the mechanism of ACE inhibition involves inhibitor interaction with an anionic binding site which is distinct from the catalytic site. Given the above, it is expected that peptide conformation, i.e. the structure adopted in a specific environment, should contribute to ACE inhibitor potency. A detailed knowledge of the mechanism of action of ACE and the conformational behaviour of ACE inhibitory peptides should lead to a better understanding of the antihypertensive potential of milk protein-derived peptides.
Physiological effects
ACE is widely distributed in mammalian tissues. It is present in plasma, lung, kidney, heart, skeletal muscle, 
nd, not determined. * Details of other casein-derived peptides/or related peptides which inhibit ACE are available within the references used to generate this Table. ² Peptide concentration required to inhibit ACE by 50 %. ³ IC 50 value given in mg/ml. § This sequence also occurs in a S1 -casein f(146±147) and f(159±160) and in b-casein f(114±115). pancreas, spleen, placenta, arteries, testes, uterus and brain.
It is also present as a brush border membrane-bound enzyme on epithelial cells of human jejunum (Ondetti & Cushman, 1982; Steve et al. 1988) .
A number of studies in spontaneously hypertensive rats (SHR) have demonstrated an antihypertensive effect following intraveneous and oral ingestion of casein-derived ACE inhibitory peptides. These peptides correspond to tryptic (Maruyama et al. 1987b) and Lactobacillus helveticus protease (Yamamoto et al. 1994 (Yamamoto et al. , 1999 ) digests of a s1 -, b-and k-casein. Oral ingestion of a tryptic digest of whole casein gave an antihypertensive effect in SHR (Karaki et al. 1990) . A study in normotensive and mildly hypertensive human volunteers reported that twice daily ingestion of 10 g of a tryptic digest of casein for 4 weeks had an antihypertensive effect (Sekiya et al. 1992) . A placebo-controlled study in hypertensive humans definitively demonstrated a significant reduction in blood pressure following daily ingestion of 95 ml of Calpis sour milk (Hata et al. 1996) . Milk fermented with Calpis sour milk starter (L. helveticus and Saccharomyces cerevisiae) contains highly potent tripeptide inhibitors of ACE, i.e. Val-Pro-Pro (b-casein f(84±86)) and Ile-Pro-Pro (b-casein f(74±76)) and k-casein f(108±110)), (Nakamura et al. 1995) . It is worth noting that the ingested dose of these ACE inhibitory peptides was in the range of only 1´2± 1´6 mg.
ACE inhibitory peptides can be produced during the manufacture of a range of dairy products. Meisel et al. (1997) demonstrated that secondary proteolysis during cheese ripening leads to the production of ACE inhibitory peptides. The ACE inhibitory activity in cheese was mainly associated with the low-molecular-weight peptide fraction. It was also demonstrated that low levels of proteolysis, in for example, fresh cheese, quarg, yoghurt and protein hydrolysate supplemented sports nutrition products, were associated with low ACE inhibitory index values (Meisel et al. 1997) . Rokka et al. (1997) demonstrated the presence of ACE inhibitory peptides (i.e. b-casein f(177±183) and f(193±202)) in UHT milk prefermented with Lactobacillus casei ssp. rhamnosus and subsequently digested with pepsin and trypsin. Recently, Mullally et al. (1997a) showed that endoproteinase (trypsin, chymotrypsin, elastase and pepsin) digests of whey protein concentrate and fractions enriched in a-lactalbumin and b-lactoglobulin could inhibit ACE in vitro. Furthermore, a tryptic fragment of b-lactoglobulin (Ala-Leu-Pro-Met-His-Ile-Arg, f(142± 148)) was identified having an ACE IC 50 42´6 mmolal (Mullally et al. 1997b) . Pihlanto-Leppa Èla È et al. (1998) identified several casein (a s1 -and b-casein) and whey (alactalbumin and b-lactoglobulin) derived ACE inhibitory peptides following digestion of cheese whey and isoelectric casein with pepsin and trypsin. No animal or human studies are as yet available on the antihypertensive potential of whey protein-derived hydrolysates/peptides. However, it has been reported that food-derived ACE inhibitory peptides with IC 50 values in the range 100±500 mmol/l can be of nutritive/physiological importance in that they could be active following oral administration (Sekiya et al. 1992) . The majority of the peptides listed in Tables 1 and 2 have ACE inhibitory potencies within this range. It is noteworthy that Yamamoto et al. (1999) demonstrated that Tyr-Pro, having an ACE IC 50 value of 720 mmol/l, could mediate a significant hypotensive effect in SHR. Tyr-Pro, which can arise from a s1 -casein f(146±147) and f(159± 160), b-casein f(114±115) and k-casein f(58±59), was found in skim milk fermented with Lactobacillus helveticus CPN4. The Tyr-Pro dipeptide may result from the hydrolytic action of starter derived post-proline dipeptidyl aminopeptidase (PPDA) activity on casein peptides. PPDA releases amino acyl proline moieties from the N-terminus of peptides (Bouchier et al. 1999) .
The antihypertensive potential of milk protein-derived peptides is dependent on the ability of these peptides to reach their target site without being degraded and as a consequence inactivated by the action of intestinal or plasma peptidases. Inhibition of ACE in lung, vascular, kidney and brain tissue by captopril, a drug commonly used in the control of blood pressure, is thought to be central to the antihypertensive effect (Velletri & Bean, 1982; Unger et al. 1985) . Resistance to peptidase degradation may be a prerequisite for an antihypertensive effect during the oral ingestion and the intravenous infusion of ACE inhibitory hydrolysates/peptides. For example, a s1 -casein f(23±27), a potent ACE inhibitor in vitro, was shown to have no hypotensive effect in vivo (Maruyama et al. 1987b) . A similar situation has been shown by Maeno et al. (1996) in the case of a s1 -casein f(104±109). The presence of ValPro-Pro and Ile-Pro-Pro in heat-treated solubilised aortal fractions of SHR fed on Calpis sour milk demonstrates the resistance of these peptides to intestinal and circulatory peptidases in addition to the absorption of these peptides from the intestine (Masuda et al. 1996) . Proline-containing peptides are generally resistant to degradation by digestive enzymes (Kim et al. 1972; Adibi & Kim, 1981) . Furthermore, tripeptides containing C-terminal Pro-Pro are reported to be resistant to proline specific peptidases (Yoshimoto et al. 1978; Mock et al. 1990) . It is interesting that the tryptic peptide, b-lactoglobulin f(142±148), was resistant to further degradation by pepsin and chymotrypsin (Mullally et al. 1997b) . On the other hand, peptide degradation or fragmentation may result in more potent ACE inhibitory activities. For example, removal of Cterminal glutamine from b-casein f(169±175) increased the in vitro ACE inhibitory potency from 1000 to 5 mmol/l, however, both b-casein f(169±174) and f(169±175) had strong antihypertensive activities in SHRs (Maeno et al. 1996) . These results emphasise the necessity of performing in vivo studies in all cases.
Several casein and whey protein-derived ACE inhibitory peptides having other biological activities have been reported. Albutensin A, bovine serum albumin f(208± 216), displays ileum contracting and relaxing activities in addition to ACE inhibitory activity (Chiba & Yoshikawa, 1991) . The casein-derived opioid peptide, b-casomorphin 7 also inhibits ACE (Meisel & Schlimme, 1994) . Recently, it was demonstrated that b-lactorphin, the whey proteinderived opioid peptide could inhibit ACE (Mullally et al. 1996) . This multifunctional bioactivity nature of milk protein peptides merits further research in terms of the general nutritive/physiological consequences of milk protein ingestion.
The majority of milk protein-derived peptides reported to date do not have ACE inhibitory potencies (Tables 1 and 2) approaching that of captopril IC 50 0´006 mmolalX However, being naturally derived these peptides would be expected not to have the side-effects associated with synthetically produced drugs used in the control of hypertension, i.e. cough and alterations in serum lipid metabolism (Ames, 1983; Seseko & Kaneko, 1985; Nakamura, 1987) .
Conclusion
Casokinins and lactokinins represent a group of bioactive peptides that have significant potential as naturally-derived agents for the prevention/control of blood pressure and related diseases. The widespread use of these peptides in functional foods/nutraceuticals requires ongoing studies, including extended clinical trials, to demonstrate their longterm efficacy and safety. 
References

